Utilizing Personalized SYNC-T Therapy in situ Vaccination & Intramural Infusion to Induce Systemic Responses in Patients with Metastatic Castrate-Resistant Prostate Cancer
Time: 3:30 pm
day: Conference Day Two
Details:
- Targeting metastatic castrate-resistant prostate cancer (mCRPC) to improve response to immunotherapy
- Showcasing the personalized in-situ tumor vaccine from device-induced partial cryolysis of a targeted solid tumor
- Combining in-situ vaccine with immediate intratumoral infusion of a multi-target proprietary drug candidate SV-102 to induce a systemic immune response
